At the 2023 Winter Clinical Hawaii Dermatology Conference, James Del Rosso, DO, adjunct clinical professor at Touro University College of Osteopathic Medicine and co-director and co-founder of the Fall and Winter Clinical Dermatology Conference, shared his key highlights: share. Session “What’s New in Medicine Cabinet? Part 1 & 2.
Transcription:
I’m Jim Del Rosso, a practicing dermatologist in Las Vegas, Nevada. There is a research center here. He is also an adjunct clinical professor at Touro University in Nevada. And I am deeply involved in dermatology. I’m actually Senior Vice President of Clinical Research and Strategy Development for Advanced Dermatology and Cosmetic Surgery, based in Maitland, Fla., where I help organize clinical research. I’m happy to be here today to give you an update on the Medicine Cabinet.
So if you’ve taken a moment to sniff what’s good about current dermatology and really stay up to date, you’ll have some new information here. We will keep you up to date with the latest information. So we cover a variety of different areas, some new topical treatments, some advanced and non-steroidal therapies, and we have aryl hydrocarbon receptor agonists.We also have PDE4 inhibitors. However, it differs from previous PDE4 inhibitors in several respects and has distinct advantages based on what we see in the data. And both of these agents have come a long way and are approved for psoriasis vulgaris in non-steroidal treatments, but are also being evaluated for atopic dermatitis. Advanced topical agents, vehicle formulations, and combination therapies are also covered. However, much focus is on advancing systemic therapies. And how we are coping with COVID-19 despite all the chaos going on in the world, dealing with lidocaine shortages and all the other turmoil. It was the year of the banner. Got a new approval. New drugs are coming out, or there are drugs that are already out there. There are new indications for some agents that were already available previously. There are many diseases that we have had great difficulty in treating, such as vitiligo, alopecia areata, and hidradenitis suppurativa. There are newer oral medications for psoriasis, even for cutaneous lupus with specific treatments. It is the first inhibitor of tyrosine kinase 2. Although this is an important mechanism and lacks the black box caveats seen with other Janus kinase inhibitors, data are also included for these agents, Janus kinase 1 and 2 inhibitors in atopic dermatitis. New information in that patient group will help define how to use these safely, without necessarily getting into potential concerns about side effects. So this is a very exciting time. I want to take what I think is important to know what is different about disease states, how you can approach them to manage them, and what you can expect from treatment, and make it really practical. So clinicians in the trenches can really feel comfortable taking advantage of these therapies. And there are already many things here that can improve patients immediately.
Edited transcript for clarity
